Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Kabir Mohammed, Myles Smith, David Mansfield, Hayden Snow, Christina Messiou, Stephen Hazell, Emma Davies, David Nicol, Stephanie O'Neill, Nabil Hujairi, Kevin J. Harrington, Nicholas Francis
Publikováno v:
Journal of Cutaneous Pathology. 47:1115-1122
Background Prostate-specific membrane antigen (PSMA) is a prostatic epithelial protein that is used as a radiotracer (68Ga-PSMA-11) for prostate cancer staging. PSMA-PET/CT (positron emission tomography/computed tomography) performed for prostate can
Autor:
Robert H.I. Andtbacka, Frances A. Collichio, Gerald Downey, Kevin J. Harrington, Howard L. Kaufman, Mark R. Middleton, Katarina Ӧhrling
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with unresectable stage IIIB
Autor:
Adel Samson, Howard L. Kaufman, Anna Olsson-Brown, Joseph J. Sacco, Robert M. Conry, Mohammed M. Milhem, Praveen K. Bommareddy, Anna C. Pavlick, Terence Duane Rhodes, Jiaxin Niu, Selda Samakoglu, Robert S. Coffin, Mark R. Middleton, Ari VanderWalder MBioeth, Kevin J. Harrington, Scott Baum, Brendan D. Curti, Alex Deterding, Jason Chesney, Francesca Aroldi, Douglas E Laux, Tawnya L. Bowles
Publikováno v:
Regular and young investigator award abstracts.
Background RP1 is an enhanced potency oncolytic HSV encoding a fusogenic protein (GALV-GP R-) and GM-CSF which has previously demonstrated tolerable safety and tumor regression alone and with nivolumab in patients with a number of tumor types. Update
Autor:
Emma King, Priyamal Silva, Derfel Ap Dafydd, Ken Lingley, Gillian Paterson, Cyrus Kerawala, Vinidh Paleri, Kent Yip, Izhar Bagwan, Miranda Payne, Pablo Nenclares, Kevin J. Harrington, Donna Begg, Neil Steven, Nancy Turnbull
Publikováno v:
European journal of cancer (Oxford, England : 1990). 138
The United Kingdom head and neck mucosal melanoma guideline development group used an evidence-based systematic approach to make recommendations in key areas of uncertainty in the field, including accurate diagnosis and staging; the appropriate treat
Autor:
Jason M. Tonne, Timothy Kottke, Richard G. Vile, Kevin J. Harrington, Laura Evgin, Adel Samson, Reuben S. Harris, Amanda L. Huff, Amy M. Molan, Christopher B. Driscoll, Phonphimon Wongthida, Hardev Pandha, Kevin G. Shim, Jill Thompson, Cynthia Wetmore, Peter Selby, Alan Melcher, Jose S. Pulido, Matthew Schuelke, Amber Miller
Publikováno v:
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
APOBEC3B, an anti-viral cytidine deaminase which induces DNA mutations, has been implicated as a mediator of cancer evolution and therapeutic resistance. Mutational plasticity also drives generation of neoepitopes, which prime anti-tumor T cells. Her
Autor:
Charles Comins, Victoria Roulstone, Guy Richard Simpson, William Rogers, Hardev Pandha, Joan N. Kyula, Alan Melcher, Kate Relph, Kevin J. Harrington
Publikováno v:
Cancer Gene Therapy. 25:148-160
There are currently numerous oncolytic viruses undergoing clinical trial evaluation in cancer patients and one agent,Talimogene laherparepvec, has been approved for the treatment of malignant melanoma. This progress highlights the huge clinical poten
Autor:
Lorna Grove, Anna L. Frauchiger, Isabella Pezzani Gruter, Kevin J. Harrington, Olivier Michielin, Josep Malvehy, Reinhard Dummer
Publikováno v:
OncoTargets and therapy
Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for the treatment of adults with unresectable melanoma that is regionally or d
Autor:
Andrew J. Hayes, Aadil A. Khan, Kevin J. Harrington, Henry G. Smith, Tim Pencavel, Michelle J. Wilkinson, Joan Kyula-Currie, Gráinne McEntee, Victoria Roulstone, David Mansfield
Publikováno v:
Oncotarget
Advanced extremity melanoma and sarcoma present a significant therapeutic challenge, requiring multimodality therapy to treat or even palliate disease. These aggressive tumours are relatively chemo-resistant, therefore new treatment approaches are ur
Autor:
Victoria Roulstone, Henry G. Smith, David Mansfield, Claire Gregory, Gráinne McEntee, Matthew C. Coffey, Michelle J. Wilkinson, Kevin J. Harrington, Joan N. Kyula
Publikováno v:
Oncotarget
// Grainne McEntee 1 , Joan N. Kyula 1 , David Mansfield 1 , Henry Smith 1, 2 , Michelle Wilkinson 1, 2 , Claire Gregory 1 , Victoria Roulstone 1 , Matt Coffey 3 , Kevin J. Harrington 1 1 Targeted Therapy Team, the Institute of Cancer Research, Londo
Autor:
Djuro Karanovic, Mitesh J. Borad, Diwakar Davar, Maria Schwaederle, Dmitriy Zamarin, Grace K. Dy, Danielle M. Townsley, Kevin J. Harrington, Evanthia Galanis, Beth Kelly
Publikováno v:
Cancer Research. 80:CT244-CT244
Background: Oncolytic viruses selectively infect tumors and activate antitumor immune responses via innate and adaptive pathways, which may potentiate the efficacy of immune checkpoint inhibitors. MEDI5395 is a recombinant Newcastle disease virus inc